inclusion criteria: * men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent * willing and able to provide informed consent * laboratory confirmed sars-cov-2 infection, with test results within past 72 hours * covid-19 symptoms, based on the following criteria: at least two of the following symptoms: fever (≥ 38ºc), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), or o at least one of the following symptoms: cough, shortness of breath or difficulty breathing (lopinavir-ritonavir platform) * access to device and internet for telehealth visits * at increased risk of developing severe covid-19 disease (at least one of the following) 1. age ≥60 years 2. presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema 3. diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment 4. hypertension, requiring at least 1 oral medication for treatment 5. immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cd4 t-cell count of \<200/mm3) 6. immunocompromised status due to medication (e.g., persons taking 20 mg or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or cancer therapies) 7. body mass index ≥30 (self-reported)

inclusion criteria: * men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent * willing and able to provide informed consent * laboratory confirmed sars-cov-2 infection, with test results within past 72 hours * covid-19 symptoms, based on the following criteria: at least two of the following symptoms: fever (≥ 38ºc), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), or o at least one of the following symptoms: cough, shortness of breath or difficulty breathing (lopinavir-ritonavir platform) * access to device and internet for telehealth visits * at increased risk of developing severe covid-19 disease (at least one of the following) 1. age ≥60 years 2. presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema 3. diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment 4. hypertension, requiring at least 1 oral medication for treatment 5. immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cd4 t-cell count of \<200/mm3) 6. immunocompromised status due to medication (e.g., persons taking 20 mg or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or cancer therapies) 7. body mass index ≥30 (self-reported)

inclusion criteria: men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent willing and able to provide informed consent laboratory confirmed sars-cov-2 infection, with test results within past 72 hours covid-19 symptoms, based on the following criteria: at least two of the following symptoms: fever (≥ 38ºc), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), or o at least one of the following symptoms: cough, shortness of breath or difficulty breathing (lopinavir-ritonavir platform) access to device and internet for telehealth visits at increased risk of developing severe covid-19 disease (at least one of the following) age ≥60 years presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment hypertension, requiring at least 1 oral medication for treatment immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cd4 t-cell count of <200/mm3) immunocompromised status due to medication (e.g., persons taking 20 mg or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or cancer therapies) body mass index ≥30 (self-reported)

inclusion criteria: men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent willing and able to provide informed consent laboratory confirmed sars-cov-2 infection, with test results within past 72 hours covid-19 symptoms, based on the following criteria: at least two of the following symptoms: fever (≥ 38ºc), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), or o at least one of the following symptoms: cough, shortness of breath or difficulty breathing (lopinavir-ritonavir platform) access to device and internet for telehealth visits at increased risk of developing severe covid-19 disease (at least one of the following) age ≥60 years presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment hypertension, requiring at least 1 oral medication for treatment immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cd4 t-cell count of <200/mm3) immunocompromised status due to medication (e.g., persons taking 20 mg or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or cancer therapies) body mass index ≥30 (self-reported)

inclusion criteria: - men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent - willing and able to provide informed consent - laboratory confirmed sars-cov-2 infection, with test results within past 72 hours - covid-19 symptoms, based on the following criteria: at least two of the following symptoms: fever (≥ 38ºc), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), or o at least one of the following symptoms: cough, shortness of breath or difficulty breathing (lopinavir-ritonavir platform) - access to device and internet for telehealth visits - at increased risk of developing severe covid-19 disease (at least one of the following) 1. age ≥60 years 2. presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema 3. diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment 4. hypertension, requiring at least 1 oral medication for treatment 5. immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cd4 t-cell count of <200/mm3) 6. immunocompromised status due to medication (e.g., persons taking 20 mg or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or cancer therapies) 7. body mass index ≥30 (self-reported)

inclusion criteria: - men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent - willing and able to provide informed consent - laboratory confirmed sars-cov-2 infection, with test results within past 72 hours - covid-19 symptoms, based on the following criteria: at least two of the following symptoms: fever (≥ 38ºc), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), or o at least one of the following symptoms: cough, shortness of breath or difficulty breathing (lopinavir-ritonavir platform) - access to device and internet for telehealth visits - at increased risk of developing severe covid-19 disease (at least one of the following) 1. age ≥60 years 2. presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema 3. diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment 4. hypertension, requiring at least 1 oral medication for treatment 5. immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cd4 t-cell count of <200/mm3) 6. immunocompromised status due to medication (e.g., persons taking 20 mg or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or cancer therapies) 7. body mass index ≥30 (self-reported)